CN115298180B - 治疗或抑制急性髓细胞白血病复发的化合物 - Google Patents
治疗或抑制急性髓细胞白血病复发的化合物 Download PDFInfo
- Publication number
- CN115298180B CN115298180B CN202180016180.0A CN202180016180A CN115298180B CN 115298180 B CN115298180 B CN 115298180B CN 202180016180 A CN202180016180 A CN 202180016180A CN 115298180 B CN115298180 B CN 115298180B
- Authority
- CN
- China
- Prior art keywords
- mmol
- pyrrolo
- pyrimidin
- phenoxyphenyl
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2020/079464 | 2020-03-16 | ||
| PCT/CN2020/079464 WO2021184154A1 (en) | 2020-03-16 | 2020-03-16 | Compounds for treating or inhibiting recurrence of acute myeloid leukemia |
| PCT/US2021/022322 WO2021188417A1 (en) | 2020-03-16 | 2021-03-15 | Compounds for treating or inhibiting recurrence of acute myeloid leukemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115298180A CN115298180A (zh) | 2022-11-04 |
| CN115298180B true CN115298180B (zh) | 2025-06-10 |
Family
ID=77767943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180016180.0A Active CN115298180B (zh) | 2020-03-16 | 2021-03-15 | 治疗或抑制急性髓细胞白血病复发的化合物 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11963960B2 (https=) |
| EP (1) | EP4121430A4 (https=) |
| JP (1) | JP7744358B2 (https=) |
| KR (1) | KR20220154164A (https=) |
| CN (1) | CN115298180B (https=) |
| AR (1) | AR121570A1 (https=) |
| AU (2) | AU2020436612A1 (https=) |
| BR (1) | BR112022018345A2 (https=) |
| CA (1) | CA3168988A1 (https=) |
| IL (1) | IL296296A (https=) |
| MX (1) | MX2022011407A (https=) |
| PE (1) | PE20230461A1 (https=) |
| PH (1) | PH12022552169A1 (https=) |
| TW (1) | TWI899184B (https=) |
| WO (2) | WO2021184154A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020436612A1 (en) | 2020-03-16 | 2022-09-01 | Flash Therapeutics, Llc | Compounds for treating or inhibiting recurrence of acute myeloid leukemia |
| RS65962B1 (sr) | 2020-05-08 | 2024-10-31 | Halia Therapeutics Inc | Inhibitori nek7 kinaze |
| EP4161933A1 (en) * | 2020-06-08 | 2023-04-12 | Halia Therapeutics, Inc. | Inhibitors of nek7 kinase |
| CN114075190A (zh) * | 2020-08-20 | 2022-02-22 | 北京诺诚健华医药科技有限公司 | 杂环类btk抑制剂 |
| CN113861179A (zh) * | 2021-10-22 | 2021-12-31 | 上海应用技术大学 | 一种新型flt3激酶抑制剂及其合成与应用 |
| WO2025124429A1 (zh) * | 2023-12-11 | 2025-06-19 | 北京康辰药业股份有限公司 | 芳香胺化合物及其药物组合物、应用 |
| CN121039131A (zh) * | 2024-01-11 | 2025-11-28 | 佩勒梅德有限公司 | 新型吡咯并三嗪衍生物及其用途 |
| KR20250157634A (ko) | 2024-04-29 | 2025-11-05 | 대한민국(질병관리청 국립보건연구원장) | Bax 활성제를 유효성분으로 포함하는 항-hiv-1 조성물 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1259950A (zh) * | 1997-03-19 | 2000-07-12 | Basf公司 | 吡咯并[2,3d]嘧啶类化合物及它们作为酪氨酸激酶抑制剂的用途 |
| US20030153752A1 (en) * | 1998-09-18 | 2003-08-14 | Hirst Gavin C. | Pyrrolopyrimidines as therapeutic agents |
| CN1520298A (zh) * | 2001-03-22 | 2004-08-11 | �����ʩ���عɷݹ�˾ | 作为治疗剂的吡唑并嘧啶类 |
| CN101674834A (zh) * | 2007-03-28 | 2010-03-17 | 环状药物公司 | 布鲁顿氏酪氨酸激酶(Bruton’s tyrosine kinase)抑制剂 |
| US20150210698A1 (en) * | 2012-07-27 | 2015-07-30 | Riken | Agent for treating or inhibiting recurrence of acute myeloid leukemia |
| CN105481862A (zh) * | 2015-01-21 | 2016-04-13 | 中国科学院合肥物质科学研究院 | Flt3激酶的新型抑制剂及其用途 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ID29028A (id) * | 1998-09-18 | 2001-07-26 | Basf Ag | Pirolopirimidina sebagai penghambat protein kinase |
| JP2003509428A (ja) * | 1999-09-17 | 2003-03-11 | アボツト・ゲー・エム・ベー・ハー・ウント・コンパニー・カーゲー | 治療薬としてのピラゾロピリミジン |
| MXPA03008560A (es) * | 2001-03-22 | 2004-06-30 | Abbot Gmbh & Co Kg | Pirazolopirimidinas como agentes terapeuticos. |
| JP2007520559A (ja) * | 2004-02-03 | 2007-07-26 | アボット・ラボラトリーズ | 治療薬としてのアミノベンゾオキサゾール類 |
| WO2007064931A2 (en) * | 2005-12-02 | 2007-06-07 | Bayer Healthcare Llc | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
| ES2545907T3 (es) * | 2005-12-29 | 2015-09-16 | Abbvie Inc. | Inhibidores de proteína quinasa |
| ES2396613T3 (es) * | 2008-05-19 | 2013-02-22 | OSI Pharmaceuticals, LLC | Imidazopirazinas e imidazotriazinas sustituidas |
| USRE48175E1 (en) * | 2012-10-19 | 2020-08-25 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
| CN105017256A (zh) * | 2014-04-29 | 2015-11-04 | 浙江导明医药科技有限公司 | 多氟化合物作为布鲁顿酪氨酸激酶抑制剂 |
| WO2016019237A2 (en) * | 2014-07-31 | 2016-02-04 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| GB201508747D0 (en) | 2015-05-21 | 2015-07-01 | Univ Edinburgh | Compounds |
| JP2019529423A (ja) * | 2016-09-15 | 2019-10-17 | 国立研究開発法人理化学研究所 | 急性骨髄性白血病を処置するためのＨＣＫ阻害剤及びＢｃｌ−２阻害剤 |
| CN113544130B (zh) | 2019-05-31 | 2024-01-09 | 西藏海思科制药有限公司 | 一种btk抑制剂环衍生物及其制备方法和药学上的应用 |
| AU2020301399B2 (en) * | 2019-06-24 | 2025-12-18 | Dana-Farber Cancer Institute, Inc. | HCK degraders and uses thereof |
| KR20220098732A (ko) * | 2019-10-08 | 2022-07-12 | 다나-파버 캔서 인스티튜트 인크. | 요법, 특히 myd88 돌연변이된 질환에 사용하기 위한 hck 억제제로서의 피라졸로피리미딘 유도체 |
| MX2022008148A (es) * | 2020-01-02 | 2022-07-21 | Dizal Jiangsu Pharmaceutical Co Ltd | Inhibidores de btk. |
| AU2020436612A1 (en) | 2020-03-16 | 2022-09-01 | Flash Therapeutics, Llc | Compounds for treating or inhibiting recurrence of acute myeloid leukemia |
-
2020
- 2020-03-16 AU AU2020436612A patent/AU2020436612A1/en active Pending
- 2020-03-16 WO PCT/CN2020/079464 patent/WO2021184154A1/en not_active Ceased
-
2021
- 2021-03-12 AR ARP210100645A patent/AR121570A1/es not_active Application Discontinuation
- 2021-03-15 AU AU2021239828A patent/AU2021239828B2/en active Active
- 2021-03-15 KR KR1020227035324A patent/KR20220154164A/ko active Pending
- 2021-03-15 JP JP2022555625A patent/JP7744358B2/ja active Active
- 2021-03-15 PH PH1/2022/552169A patent/PH12022552169A1/en unknown
- 2021-03-15 MX MX2022011407A patent/MX2022011407A/es unknown
- 2021-03-15 PE PE2022001990A patent/PE20230461A1/es unknown
- 2021-03-15 US US17/201,827 patent/US11963960B2/en active Active
- 2021-03-15 BR BR112022018345A patent/BR112022018345A2/pt not_active Application Discontinuation
- 2021-03-15 IL IL296296A patent/IL296296A/en unknown
- 2021-03-15 EP EP21772015.0A patent/EP4121430A4/en active Pending
- 2021-03-15 WO PCT/US2021/022322 patent/WO2021188417A1/en not_active Ceased
- 2021-03-15 CN CN202180016180.0A patent/CN115298180B/zh active Active
- 2021-03-15 CA CA3168988A patent/CA3168988A1/en active Pending
- 2021-03-16 TW TW110109254A patent/TWI899184B/zh active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1259950A (zh) * | 1997-03-19 | 2000-07-12 | Basf公司 | 吡咯并[2,3d]嘧啶类化合物及它们作为酪氨酸激酶抑制剂的用途 |
| US20030153752A1 (en) * | 1998-09-18 | 2003-08-14 | Hirst Gavin C. | Pyrrolopyrimidines as therapeutic agents |
| CN1520298A (zh) * | 2001-03-22 | 2004-08-11 | �����ʩ���عɷݹ�˾ | 作为治疗剂的吡唑并嘧啶类 |
| CN101674834A (zh) * | 2007-03-28 | 2010-03-17 | 环状药物公司 | 布鲁顿氏酪氨酸激酶(Bruton’s tyrosine kinase)抑制剂 |
| US20150210698A1 (en) * | 2012-07-27 | 2015-07-30 | Riken | Agent for treating or inhibiting recurrence of acute myeloid leukemia |
| CN105481862A (zh) * | 2015-01-21 | 2016-04-13 | 中国科学院合肥物质科学研究院 | Flt3激酶的新型抑制剂及其用途 |
Non-Patent Citations (3)
| Title |
|---|
| Hitomi Yuki等.Activity cliff for 7-substituted pyrrolo-pyrimidine inhibitors of HCK explained in terms of predicted basicity of the amine nitrogen.《Bioorganic & Medicinal Chemistry》.2017,第25卷(第16期),全文. * |
| Yasuko Koda.Identification of pyrrolo[2,3-d]pyrimidines as potent HCK and FLT3-ITD dual inhibitors.《Bioorganic & Medicinal Chemistry Letters》.2017,第27卷全文. * |
| Yoriko Saito等.A Pyrrolo-Pyrimidine Derivative Targets Human Primary AML Stem Cells in Vivo.《RESEARCH ARTICLE》.2013,第5卷(第181期),全文. * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220154164A (ko) | 2022-11-21 |
| EP4121430A1 (en) | 2023-01-25 |
| AR121570A1 (es) | 2022-06-15 |
| TWI899184B (zh) | 2025-10-01 |
| WO2021184154A1 (en) | 2021-09-23 |
| JP2023518035A (ja) | 2023-04-27 |
| CA3168988A1 (en) | 2021-09-23 |
| PE20230461A1 (es) | 2023-03-14 |
| IL296296A (en) | 2022-11-01 |
| AU2021239828B2 (en) | 2025-06-26 |
| AU2021239828A1 (en) | 2025-04-03 |
| BR112022018345A2 (pt) | 2022-11-08 |
| WO2021188417A1 (en) | 2021-09-23 |
| US11963960B2 (en) | 2024-04-23 |
| US20210299128A1 (en) | 2021-09-30 |
| JP7744358B2 (ja) | 2025-09-25 |
| PH12022552169A1 (en) | 2024-01-29 |
| AU2020436612A1 (en) | 2022-09-01 |
| TW202200583A (zh) | 2022-01-01 |
| EP4121430A4 (en) | 2024-04-17 |
| CN115298180A (zh) | 2022-11-04 |
| MX2022011407A (es) | 2022-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN115298180B (zh) | 治疗或抑制急性髓细胞白血病复发的化合物 | |
| US10273239B2 (en) | Spiro-lactam NMDA receptor modulators and uses thereof | |
| TW202334138A (zh) | 癌症治療方法 | |
| TWI436769B (zh) | 類Ｐｏｌｏ激酶抑制劑 | |
| CN102548557B (zh) | 用于降低β-淀粉状蛋白生成的化合物 | |
| TWI596095B (zh) | Dihydropyridazine-3,5-dione derivatives | |
| EP4129996A1 (en) | Novel aminopyrimidine egfr inhibitor | |
| CN102827170A (zh) | 治疗活性组合物和它们的使用方法 | |
| JP2020528062A (ja) | ピペラジンヘテロアリール誘導体、その製造方法、およびその医薬での使用 | |
| EA012926B1 (ru) | Пирролопиримидиновые соединения, относящиеся к a-селективным антагонистам, их синтез и применение | |
| JP5916975B1 (ja) | ナトリウム依存性リン酸トランスポーター阻害剤を含有する医薬 | |
| TW201309703A (zh) | 作為蛋白質酪胺酸激酶抑制劑之新穎磺醯胺哌□衍生物及其醫藥用途 | |
| EP3576743B1 (en) | 5-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-5-azaspiro[2 5]octane-8-carboxylic acid derivatives as jak kinase inhibitors | |
| HK40083594A (en) | Compounds for treating or inhibiting recurrence of acute myeloid leukemia | |
| WO2024218235A1 (en) | Pyrrolopyrazine compounds, preparation thereof and therapeutic uses thereof | |
| EP4577535A1 (en) | Jak1/jak2/tyk2 inhibitors for topical treatment of dermatological diseases | |
| EA047455B1 (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-а]ПИРИДИНИЛА И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ | |
| HK1212700B (en) | Dihydropyridazine-3,5-dione derivative | |
| HK1235279A1 (en) | Pharmaceutical containing sodium-dependent phosphate transporter inhibitor | |
| HK1235279B (zh) | 含有钠依赖性磷酸转运蛋白抑制剂的药物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40083594 Country of ref document: HK |
|
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20250514 Address after: Japan Applicant after: Japan Institute of Physics and Chemistry Country or region after: Japan Address before: Massachusetts, USA Applicant before: Fuleishu Medical Co.,Ltd. Country or region before: U.S.A. |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |